<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524875</url>
  </required_header>
  <id_info>
    <org_study_id>8657</org_study_id>
    <nct_id>NCT00524875</nct_id>
  </id_info>
  <brief_title>Effect of Intravitreal Bevacizumab on Early Post-Vitrectomy Hemorrhage in Diabetic Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether bevacizumab 1-2 weeks before vitrectomy is
      effective in lowering the rate of early post-vitrectomy vitreous hemorrhage in diabetic
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes is the leading cause of blindness in the age range of 20-64 years. Pars plana
      vitrectomy may be indicated for the management of advanced proliferative diabetic
      retinopathy. Early post-vitrectomy hemorrhage in diabetic patients is relatively common; it
      occurs in 29% -75% of patients in the first month after surgery. This may cause delayed
      visual rehabilitation and detection of surgical complications such as retinal break or
      detachment. Preliminary reports such as case series reported by Spaide RF, et al showed
      beneficial effect of bevacizumab in proliferative diabetic retinopathy complicated by
      vitreous hemorrhage.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">September 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>early post-vitrectomy vitreous hemorrhage</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual improvement</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal bevacizumab injection 1-2 weeks before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham injection (needleless syringe pressed against conjunctiva)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All eyes who are candidate for pars plana vitrectomy because of complications of
             diabetic retinopathy such as nonclearing vitreous hemorrhage, tractional retinal
             detachment threatening macula, active progressive PDR

        Exclusion Criteria:

          -  One eye patient

          -  Best corrected visual acuity better than 20/50

          -  Pregnancy

          -  Use of internal tamponade such as silicone oil during surgery

          -  Concurrent ophthalmic surgery such as cataract extraction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Ahmadieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Research Center of Shaheed Beheshti Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hamid Ahmadieh, MD</last_name>
    <phone>+98 21 22585952</phone>
    <email>hahmadieh@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamid Ahmadieh, MD</name>
      <address>
        <city>Tehran</city>
        <zip>16666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamid Ahmadieh, MD</last_name>
      <phone>+98 21 22585952</phone>
      <email>hahmadieh@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <last_update_submitted>September 4, 2007</last_update_submitted>
  <last_update_submitted_qc>September 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2007</last_update_posted>
  <keyword>Proliferative diabetic retinopathy</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Early post-vitrectomy vitreous hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

